MICAD adds 17 molecular imaging, contrast agents

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

The Molecular Imaging Probes and Contrast Agents Database (MICAD), created at the National Center for Biotechnology Information, National Institutes of Health via the PubMed/MedLine databases and other sources, has added 17 new agents, increasing the total to 841 agents in the database.

The new PET agents are:

  • 64Cu-PEIĀ  which targets heparin sulfate proteoglycans;
  • [11C]Methoxy-Sch225336 which targets cannabinoid CB2 receptor (CB2R);
  • [11C]SU11274 which targets mesenchymal-epithelial transition factor (MET); and
  • [11C]SL25.1188 which targets monoamine oxidase B (MAO-B).

The new SPECT agents are:

  • 67Ga-DOTA-GlyGlu-CycMSH which targets melanocortin-1 receptor (MC1R);
  • [186Re]MAMA-HBP and [186Re]MAMA-BP which both targets farnesyl disphosphate (pyrophosphate) synthase;
  • [125I]IodoDPA-713 which targets peripheral-type benzodiazepine receptor (PBR), also known as translocator protein (TSPO);
  • [125I]-BH-Exendin(9-39) which targets glucagon-like peptide-1 (GLP-1) receptor;
  • 125I-EGFR-Fab which targets epidermal growth factor receptor (EGFR);
  • 111In-[DTPA1-Lys3,Tyr4]-BN which targets gastrin-releasing peptide receptor (GRPR);
  • 111In-DOTA-E3-uroguanylin which targets receptor guanylate cyclase C (GC-C);
  • 99mTc-PR81 which targets mucin; and
  • 99mTc-DTPA-TOR which targets estrogen receptor.

The new optical agents are:

  • tAB50-Cy5 which targets caspase-3 and caspase-7;
  • Legumain probe 1 which targets legumain/asparaginyl endopeptidase; and
  • AnxB12 Cys101,Cys260-IANBD which targets phosphatidylserine.